Nasal allergies in the Latin American population: results from the Allergies in Latin America survey.
Allergies in Latin America is the first cross-national survey that describes the symptoms, impact, and treatment of nasal allergies (NAs) in individuals >or=4 years old in Latin America (LA). In total, 22,012 households across the Latin American countries of Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Peru, and Venezuela were screened for children, adolescents, and adults with a diagnosis of NA and either symptoms or treatment in the past 12 months. A total of 1088 adults and 457 children and adolescents were included and the sample was probability based to ensure valid statistical inference to the population. Approximately 7% of the LA population was diagnosed with NAs with two of three respondents stating that their allergies were seasonal or intermittent in nature. A general practice physician or otolaryngologist diagnosed the majority of individuals surveyed. Nasal congestion was the most common and bothersome symptom of NAs. Sufferers indicated that their symptoms affected productivity and sleep and had a negative impact on quality of life. Two-thirds of patients reported taking some type of medication for their NAs, with a roughly equal percentage of patients reporting taking over-the-counter versus prescription medications. Changing medications was most commonly done in those reporting inadequate efficacy. The most common reasons cited for dissatisfaction with current medications were related to inadequate effectiveness, effectiveness wearing off with chronic use, failure to provide 24-hour relief, and bothersome side effects (e.g., unpleasant taste and retrograde drainage into the esophagus). Findings from this cross-national survey on NAs have confirmed a high prevalence of physician-diagnosed NAs and a considerable negative impact on daily quality of life and work productivity as well as substantial disease management challenges in LA. Through identification of disease impact on the LA population and further defining treatment gaps, clinicians in LA may better understand and treat NAs, thus leading to improvements in overall patient satisfaction and quality of life.
Neffen
Hugo
H
Respiratory Medicine Unit, Children's Hospital Orlando Alassia, Santa Fe, Argentina. hugoneffen@arnet.com.ar
Mello
Joao F
JF
Sole
Dirceu
D
Naspitz
Charles K
CK
Dodero
Alberto Eduardo
AE
Garza
Héctor León
HL
Guerra
Edgard Novelo
EN
Baez-Loyola
Carlos
C
Boyle
John M
JM
Wingertzahn
Mark A
MA
D000293:Adolescent; D018926:Anti-Allergic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D003625:Data Collection; D006801:Humans; D007843:Latin America / Q000453:epidemiology; D017060:Patient Satisfaction; D011788:Quality of Life; D012221:Rhinitis, Allergic, Perennial / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*
D018926:Anti-Allergic Agents